|
|
Article: U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories.
- Article from:
- PR Newswire
- Article date:
- July 21, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TOKYO and WOODCLIFF LAKE, N.J., July 21 /PRNewswire/ -- With respect to Eisai's patent infringement lawsuit against Teva Pharmaceuticals and Dr. Reddy's Laboratories concerning Aciphex(R) (generic name: rabeprazole sodium tablets, Product Name in Japan: Pariet(R)), Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announce that the United States Court of Appeals for the Federal Circuit has affirmed both the United States District Court for the Southern District of New York's summary judgment ruling on the validity of Eisai's composition of matter patent and its ruling on the enforceability of the composition of matter patent.
Eisai ...
Related newspaper, magazine, and journal articles:
|
|
Article: Eisai rises in the west
Pharmaceutical Executive;
February 1, 2003 ;
700+ words
... ... anchor in the United States. In turn, its US subsidiary Eisai Inc. is playing ... building up Eisai's reputation ... operations in the United States, all-as ... Matsuno. "Eisai wanted to build ... company in the United States, but doing ...
|
|